Cell Kinetic Study of Bromodeoxyuridine (BrdU) in Prostate Cancer
I. Measure the potential doubling times of multifocal adenocarcinomas of the prostate using
II. Determine whether the doubling times of multifocal carcinomas occurring within a single
prostate are consistent with a model in which low-volume carcinomas have slow doubling times
and high-volume carcinomas have fast doubling times.
Patients receive broxuridine IV over 30 minutes on day -1. Approximately 12-96 hours later,
patients undergo surgery to remove the prostate. Tumor tissue is examined by immunostaining
for the presence of broxuridine to determine doubling times of the tumor.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Average doubling time between low and high volume tumors
Up to 3 years
University of Colorado, Denver
United States: Food and Drug Administration
|University of Colorado||Denver, Colorado 80217|